Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease

NCT03208465 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus
Coronary Disease

Interventions

DRUG: Empagliflozin
DRUG: Sitagliptin

Sponsor

CHEOL WHAN LEE, M.D., Ph.D